Thus, further research into lymphodepleting regimens that add macrophage depletion is warranted, especially in groups at high risk of CRS such as patients with high tumor burden, high LDH, or high levels of CRP at the time of CAR-T therapy. The gene discussed is CRP; the disease is neoplasm.